95 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated … , price, the potential advantages of alternative products, the level of generic competition, and the availability of coverage and adequate reimbursement
8-K
EX-1.1
xuw2sdgp5g5qqbs
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
424B5
km980k
29 Nov 23
Prospectus supplement for primary offering
5:05pm
424B5
eb73rr
23 Jun 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-1.1
fly a6d7to95t9u0pxas
23 Jun 22
Other Events
4:04pm
424B5
9prrtk9ootv
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
zy4m w6ztqcp0fv
1 Mar 22
Prospectus supplement for primary offering
5:12pm